NCT01491529 - Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

DyskinesiasParkinson DiseaseMovement DisordersParkinsonian DisordersAnti-Dyskinesia Agents

Interventions

DRUG

AFQ056

"AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~* Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~* Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"

DRUG

Placebo

Placebo for AFQ056 will be supplied as oral tablets.

Trial Locations (39)

1011

Novartis Investigative Site, Lausanne

1085

Novartis Investigative Site, Budapest

3010

Novartis Investigative Site, Bern

7400

Novartis Investigative Site, Kaposvár

12163

Novartis Investigative Site, Berlin

14547

Novartis Investigative Site, Beelitz-Heilstätten

20014

Novartis Investigative Site, Donostia / San Sebastian

25123

Novartis Investigative Site, Brescia

28006

Novartis Investigative Site, Madrid

33604

Novartis Investigative Site, Pessac

33612

Novartis Investigative Site, Tampa

34128

Novartis Investigative Site, Kassel

39100

Novartis Investigative Site, Bolzano

40225

Novartis Investigative Site, Düsseldorf

44791

Novartis Investigative Site, Bochum

53233

Novartis Investigative Site, Milwaukee

56126

Novartis Investigative Site, Pisa

59037

Novartis Investigative Site, Lille

63003

Novartis Investigative Site, Clermont-Ferrand

66160

Novartis Investigative Site, Kansas City

80113

Novartis Investigative Site, Englewood

80804

Novartis Investigative Site, München

81675

Novartis Investigative Site, München

82606

Novartis Investigative Site, Bratislava

83305

Novartis Investigative Site, Bratislava

86021

Novartis Investigative Site, Poitiers

94089

Novartis Investigative Site, Sunnyvale

A-6020

Novartis Investigative Site, Innsbruck

A-4020

Novartis Investigative Site, Linz

A-1220

Novartis Investigative Site, Vienna

N6A 5A5

Novartis Investigative Site, London

04103

Novartis Investigative Site, Leipzig

07646

Novartis Investigative Site, Stadtroda

H-6725

Novartis Investigative Site, Szeged

00163

Novartis Investigative Site, Roma

00179

Novartis Investigative Site, Roma

08025

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona

08190

Novartis Investigative Site, Sant Cugat del Vallès